These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 1900342

  • 1. Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia.
    Horiuchi I, Ohya T, Tazuma S, Mizuno T, Takizawa I, Kajiyama G.
    Metabolism; 1991 Mar; 40(3):226-30. PubMed ID: 1900342
    [Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, van Blankenstein M.
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [Abstract] [Full Text] [Related]

  • 3. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.
    Muraca M, Baggio G, Miconi L, Vilei MT, Martini S, Gabelli C, Belluco C, Lise M, Crepaldi G.
    Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632
    [Abstract] [Full Text] [Related]

  • 4. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S, Takizawa I, Kunita T, Mizuno T, Watanabe T, Teramen K, Horikawa K, Ochi H, Yamashita Y, Aihara N.
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [Abstract] [Full Text] [Related]

  • 5. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
    Koide K, Hayashi K, Horiuchi I, Kajiyama G.
    Biochim Biophys Acta; 1989 Sep 11; 1005(1):65-71. PubMed ID: 2505850
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of ML-236B (compactin) on biliary excretion of bile salts and lipids, and on bile flow, in the rat.
    Kempen HJ, De Lange J, Vos-Van Holstein MP, Van Wachem P, Havinga R, Vonk RJ.
    Biochim Biophys Acta; 1984 Jul 26; 794(3):435-43. PubMed ID: 6743675
    [Abstract] [Full Text] [Related]

  • 15. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B.
    N Engl J Med; 1990 Jul 26; 323(4):224-8. PubMed ID: 2114543
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of cholestyramine treatment on biliary lipid secretion rates in normolipidaemic men.
    Carrella M, Ericsson S, Del Piano C, Angelin B, Einarsson K.
    J Intern Med; 1991 Mar 26; 229(3):241-6. PubMed ID: 2007842
    [Abstract] [Full Text] [Related]

  • 20. Effect of pravastatin on newly-secreted very low density lipoprotein composition in rats.
    Yoshino G, Matsushita M, Iwai M, Morita M, Matsuba K, Hirano T, Furukawa S, Kazumi T, Baba S.
    Horm Metab Res; 1991 Apr 26; 23(4):193-5. PubMed ID: 1908431
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.